BioSpace News Archive

Anthos Therapeutics, announced today that it has completed enrollment in the AZALEA-TIMI 71 clinical trial, a Phase 2 randomized, multicenter, active-controlled study evaluating the safety and tolerability of abelacimab in comparison with open-label rivaroxaban in patients with atrial fibrillation at moderate-to-high risk of stroke.

Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company’s mission of connecting innovation to purpose.

Massive Bio, Inc. announced the launch of its 100K CANCER CLINICAL TRIAL SINGULARITY PROGRAM.

Aerami Therapeutics Holdings, Inc., a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and chronic diseases, and FoxWayne Enterprises Acquisition Corp., a special purpose acquisition company, announced they have entered into a definitive business combination agreement.

Capital for commercialization of SparkRx for adolescent depression and exploration of new digital therapeutics to address mental health needs in pediatrics.

IMMUNOPRECISE ANTIBODIES LTD. today announced that it will host a conference call to discuss its financial results and recent business highlights for second quarter fiscal year 2022 on December 13, 2021, after the close of market.

Scopus BioPharma Inc.(Nasdaq: “SCPS”) today mailed a letter to its stockholders in connection with the Company’s Annual Meeting of Stockholders (the “Annual Meeting”) that will be reconvened on Monday, December 20, 2021 at 11:30 a.m., Eastern time.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced participation in the following conferences in December.

Linus Biotechnology Inc. today announced that the U.S. Food and Drug Administration Center for Devices and Radiological Health has granted the Company’s StrandDx™-ASD diagnostic aid the designation as a Breakthrough Device for Autism Spectrum Disorder (ASD).

Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) Annual Meeting.